Seattle Genetics | SGEN - سرمایه عادی



سرمایه عادی تغییر دادن تاریخ
AbbVie USD 1.77B 1.75B 2025-06
Acadia Pharmaceuticals USD 169.18M 470K 2025-12
Agios Pharmaceuticals USD 58.45M 169K 2025-12
Amgen USD 539M 1000K 2025-12
Astellas Pharma JPY 1.79B 195K 2025-12
Bayer EUR 982.42M 0 2025-12
Biogen USD 146.7M 200K 2025-09
BioMarin Pharmaceutical USD 192.3M 201K 2025-12
Bristol-Myers Squibb USD 2.04B 1.74B 2025-09
Celldex Therapeutics USD 66.55M 102K 2025-12
Daiichi Sankyo JPY 1.85B 9K 2025-12
Eisai JPY 282.11M 1000 2025-12
Eli Lilly USD 946.83M 354.23M 2025-06
Esperion Therapeutics USD 112K 11K 2023-09
Exelixis USD 268.1M 2.03M 2025-09
Genmab DKK 10M 56M 2025-03
Gilead Sciences USD 1.24B 1000K 2025-12
GlaxoSmithKline GBP 4.08B 49.43M 2025-12
Glaxosmithkline GBP 4.03B 2.68B 2025-09
Incyte USD 198.46M 2.33M 2025-12
Insmed USD 214.26M 1.67M 2025-12
Karyopharm Therapeutics USD 13K 0 2024-09
MacroGenics USD 63.26M 62.63M 2025-09
Merck USD 2.49B 15.79M 2025-09
Moderna USD 391M 2M 2025-09
Nektar Therapeutics USD 19K 0 2024-09
Novartis USD 1.94B 23.4M 2025-06
Pfizer USD 5.69B 1000K 2025-09
Puma Biotechnology USD 5K 0 2024-06
Regeneron Pharmaceuticals USD 105.3M 1.1M 2025-09
Sarepta Therapeutics USD 104.96M 196K 2025-12
Takeda JPY 1.58B 2K 2025-12
Teva Pharmaceutical Industries USD 1.15B 0 2025-12
Vertex Pharmaceuticals USD 254M 0 2025-12
Xencor USD 71.87M 529K 2025-12